Search Results

An Interview With Suresh Vedantham, MD

The national principal investigator of the ATTRACT study shares his insights on DVT treatment, regulatory hindrances in the venous space, and the progression of interventional radiology fellowships.

Deep Venous Disease Patient Advocacy

Moderator Suresh Vedantham, MD, asks Leslie Lake, Volunteer President of the National Blood Clot Alliance and bilateral PE survivor, about patient and physician engagement in the organization, educational and outreach initiatives in deep vein thrombosis/pulmonary embolism, how physicians can get involved in patient advocacy, and more.

Improving the CHEST Guidelines for VTE Care

Suresh Vedantham, MD, shares his perspective on how the current CHEST guidelines serve the endovascular community and how they might be improved in the next edition.

Optimizing Deep Venous Treatment

By Suresh Vedantham, MD

Meeting the Challenge

An update on the ATTRACT trial.

By Suresh Vedantham, MD

C-TRACT: What We've Learned About DVT Trial Design

Dr. Suresh Vedantham discusses his experience with C-TRACT and other DVT trials and their potential implications on future trial design and treatment standards.

With Suresh Vedantham, MD

The ATTRACT Trial

An update on the future of DVT therapy.

By Suresh Vedantham, MD

Exploring the Potential for a “Response Team” Concept in Deep Vein Thrombosis

Dr. Suresh Vedantham asks Drs. Pavan Kavali and Kristen Sanfilippo about possible benefits of a DVT response team model, barriers to adoption, patient selection and medical management considerations, and implications for clinical research.

The Best Answers Come From the Hardest Questions . . . So Keep Asking ‘Em

By Suresh Vedantham, MD

New Messages, New Media: ATTRACT Study Update

Renewing the commitment to find the best possible treatment for future DVT patients.

By Suresh Vedantham, MD

Postprocedural Management After Endovascular DVT Therapy

Tips for providing diligent and tailored follow-up care to optimize clinical outcomes after endovascular intervention.

By Suresh Vedantham, MD

What if the ATTRACT Trial Had Been Positive?

Reflections on what is lost and gained when a well-designed trial produces unexpected results.

By Suresh Vedantham, MD

C-TRACT Trial: Coming Together to Tackle Chronic DVT

Why C-TRACT is needed, its study design, and how current endovascular practitioners can support it.

By Suresh Vedantham, MD

Panel Discussion: Perspectives on Acute Deep Vein Thrombosis in 2021

Moderator: Suman M. Wasan, MD
Panelists: Misaki Kiguchi, MD; Michael Lichtenberg, MD, FESC; Mahmood Razavi, MD; and Suresh Vedantham, MD

Who Are Your “Never Stent” Patients, and Why?

Perspectives on the anatomic concerns, patient characteristics, and procedural factors that warrant avoiding venous stenting.

With Kathleen Gibson, MD; Gerard O’Sullivan, MD; Suresh Vedantham, MD; and Rick de Graaf, MD, PhD

Playing Offense in Postthrombotic Syndrome: The C-TRACT Trial Opportunity

Why a randomized controlled trial is important to evaluate iliac vein stenting in PTS and how the C-TRACT trial can help resolve unanswered questions.

By Suresh Vedantham, MD

Exploring the Pulmonary Embolism Interventional Trial Landscape

The current PE clinical study landscape, how PE trials compare with DVT trials, lessons learned from single-center studies, strengths and limitations of new-generation trials, study design considerations, and key outcomes of interest.

With Stavros V. Konstantinides, MD, and Suresh Vedantham, MD

ATTRACT 2-Year Data and Commentary

Two-year ATTRACT data show that anticoagulation alone is best for most deep vein thrombosis; pharmacomechanical catheter-directed thrombolysis benefits seen in certain iliofemoral patients.